Shanghai Null Hypothesis Information Technology Co., Ltd. was established in 2019 to develop intelligent medical content products. Combining data science and medical expertise, we simplify the process of knowledge extraction and translation for academic engagement.

　Founded in June 2019, Proviva Therapeutics is a research and development company of innovative antitumor biological drugs based in China and facing the world. The founding team has held core R&D positions in several pharmaceutical companies such as GSK, and has over 20 years of experience in antibody discovery, engineering transformation, and immune drug research and development, as well as rich entrepreneurial experience.

Accunome Biotechnology Co., Limited (“Accunome” ) was founded in Xiuzhou National High-Tech Park（Jiaxing, Zhejiang）in July 2018, and has set up wholly-owned R&D subsidiaries in San Diego (USA) and Shanghai with full capabilities of R&D and manufacturing for both instruments and reagents in IVD industry.As an innovation driven company in the health care industry, Accunome has launched its first sample-to-answer molecular diagnostics platform DXcellence System with a broad menu of tests for critical diseases.

HumaDX is a medical company with innovative technology. Relying on the accumulation in material science, in vitro diagnostic technology, and instrument manufacture for many years, the company devotes to providing clinical laboratories with the full-automatic, high-throughput multiplex platform and corresponding reagents based on multiplex technology focusing on the field of immunological diseases and rare diseases, and expands the emerging market in IVD industry. 

Shanghai Bendao Gene Technology Co., Ltd. was established in 2018. The sponsors are top scientists in the field of gene therapy, industrial experts with international pharmaceutical company background, and safety evaluation toxicology experts with preclinical drug evaluation experience. The consultant team includes authoritative experts in the industry, clinicians from large domestic tertiary hospitals, gene therapy and immunology experts from the world's top 100 universities, and executives of listed pharmaceutical companies.

　The office address of Xinyoukang Pharmaceutical Technology (Nanjing) Co., Ltd. is located in Nanjing, the ancient capital of the Six Dynasties and the capital of Jiangsu Province, Room 9268, Building A, Phase I, Zhongdan Ecological Life Science Industrial Park, No. 31, Xinjinhu Road, Jiangbei New District, Nanjing City, Nanjing, October 2018 It was registered and established in Nanjing Administration for Industry and Commerce on the 19th. It has always provided customers with good products and technical support, and sound after-sales service. It is mainly engaged in medical research and experimental development (excluding human stem cells, gene diagnosis and treatment technology development and application) ; Manufacturing of biological drugs, manufacturing of sanitary materials and medical supplies (items subject to approval in accordance with the law can only carry out business activities after being approved by relevant departments).

　Nanjing Olimex Medical Technology Co., Ltd. was established in 2017. The company's strategy is to follow up quickly, that is, to select targets that have completed clinical proof-of-concept as "me-too" drugs, which can greatly reduce the risk of research and development. The field currently selected is mainly cancer, and the research and development follow the international mainstream anti-tumor drug research and development direction.

Jiangsu Baiyouda Life Technology Co., Ltd. was established in 2015. Its headquarter is located in North High-tech Park, Nantong City, 160km away from downtown Shanghai. The production plant exceeds 2000m² and employs more than 60 people. Company research and development

Founded in 2018, Yingshi Bio is a cutting-edge biotechnology company in the clinical research and development stage. Taking disease biology as the source of innovation, the company focuses on breaking through the drug resistance and metastasis of tumors, especially anti-PD1 drug resistance, and deeply explores the research and development of new drugs targeting the tumor microenvironment. A new drug research and development company in China and influencing the world. The company has established Shanghai, Beijing and Nanjing teams in China, and has high-level translational medicine and clinical development teams across China, the United States, Canada and Australia. The company has built a unique and effective global R&D pipeline through product introduction, joint research and development, and independent innovation, and is committed to becoming "the first in its class" and "the best in its class".

The entrepreneurial team of Zhongji Zhiyao Company brings together Xiehe students and top talents in the industry. The main founders all have study and work experience in Union Medical University. A solid scientific research ability is a valuable asset for an entrepreneurial team. The Chinese head office was established in the Xiongan New Area, which is a millennium plan, and at the same time invested in the construction of a GMP pilot test base in the new area. In order to recruit talents, the North R&D Center will be built in the Beijing Economic and Technological Development Zone, and the South R&D Center will be established at the same time. The company provides fast, safe and stable carrier customization services for global scientific research institutions, biopharmaceutical companies and medical institutions. At the same time, the company bases itself on its own advantages and combines proprietary technology to develop gene therapy drugs for single-gene genetic diseases.